Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Pivalic acid | HCID 6417 | — |
| Reactant | Potassium Carbonate | HCID 11430 | — |
| Reactant | 2,6-Dibromo-4-methylpyridine | HCID 11288174 | — |
| Reactant | HCID 178451152 | HCID 178451152 | — |
| Catalyst | HCID 178418397 | HCID 178418397 | — |
| Solvent | Ethyl Acetate | HCID 8857 | — |
| Solvent | Dimethylacetamide | HCID 31374 | — |
| Product | HCID 178451149 | HCID 178451149 | — |
Reaction Steps
To a vial were added 2,6-dibromo-4-methylpyridine (121 mg, 0.482 mmol), cis-butyl 4-[1-hydroxy-1-(1,3-thiazol-2-yl)ethyl]cyclohexanecarboxylate (75 mg, 0.241 mmol), potassium carbonate (100 mg, 0.722 mmol), pivalic acid (5.59 μl, 0.048 mmol), tetrakis(triphenylphosphine)palladium(0) (11.1 mg, 9.63 μmol) and N,N-dimethylacetamide (760 μl). The vial was sealed and placed under argon through 3 cycles of evacuation and argon flushing then reacted at 80° C. overnight. The resulting mixture was cooled, diluted with ethyl acetate, filtered through a plug of CELITE and concentrated. The residue was purified by column chromatography on silica gel (0-100% ethyl acetate/hexanes) to afford racemic-cis-butyl 4-{1-[5-(6-bromo-4-methylpyridin-2-yl)-1,3-thiazol-2-yl]-1-hydroxyethyl}-cyclohexanecarboxylate.
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US09120785B2 |
|---|
| Source dataset | uspto-grants-2015_09 |
|---|
| ORD ID | ord-34557774aa334d7f9ee1315bf41f10c6 |
|---|
| Source note | uspto-grants-2015_09 |
|---|